Epidaza (chidamide)

P2, N=32, Active, not recruiting, Liping Dou

P2, N=120, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Dec 2027 --> Sep 2027

P2, N=73, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial completion date: Dec 2024 --> Apr 2026 | Trial primary completion date: Dec 2023 --> Oct 2025

P2, N=46, Not yet recruiting, Dongguan People's Hospital

Despite CHOP, CHOEP, DA-EPOCH, and AC-CHOP (azacitidine plus chidamide) regimens, the patient experienced primary refractory disease and died 6 months from diagnosis following COVID-19 superinfection. To our knowledge, this is the first case reporting single-cell transcriptomic comparison of skin versus blood compartments in PTCL-NOS, revealing how cutaneous microenvironment sculpts aggressive malignant phenotypes and providing potential targets for compartment-specific therapy.

For example, a recent study in Communications Medicine has demonstrated that histone deacetylase inhibitors de-repress transcription of a tumor suppressor GSDME in B-cell lymphoma cells, and synergize with cisplatin and etoposide to promote GSDME cleavage by caspase-3 and subsequent pyroptosis of lymphoma cells. Furthermore, the anti-lymphoma efficacy of this combination therapy in vivo depends on CD8 T cells. This article provides a brief introduction of the pyroptosis pathway in cancer, comments on this promising 'One action, two benefits' therapeutic strategy for cancer treatment, and discusses the significance and unaddressed questions in recent therapeutic studies targeting pyroptosis-suppressing mechanisms in cancer.

P1, N=18, Not yet recruiting, First Affiliated Hospital of Zhejiang University

P2, N=27, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting

P2, N=15, Not yet recruiting, Zhongshan Hospital (Xiamen), Fudan University

P1, N=22, Completed, Beijing 302 Hospital | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Dec 2025 | Not yet recruiting --> Completed

A 59-year-old woman with stage IIIA HR+/HER2- breast cancer underwent modified radical mastectomy in 2016, followed by adjuvant AC-P (doxorubicin hydrochloride 70 mg, cyclophosphamide 800 mg, and paclitaxel liposomes 180 mg) chemotherapy, radiotherapy, and letrozole maintenance...Since palbociclib was not yet covered by insurance, she received an initial chidamide + exemestane therapy, which proved ineffective. Using second-line palbociclib combined with fulvestrant and zoledronic acid therapy, disease stabilization was achieved for up to 12 months...As of September 2023, the patient has remained progression-free for >20 months and experienced only manageable grade 2 diarrhea. This case suggests that sequential CDK4/6 inhibition could help achieve >20 months of progression-free disease control in a patient with bone-only HR+/HER2- MBC after clinical progression during prior palbociclib-based therapy and underscored the need for biomarker-guided strategies in this distinct population.

In LSCC, USP28 stabilizes c-MYC, ΔNp63, and SREBP2; in LUAD, USP22 emerges as an integrative node coupling proliferation, EZH2-mediated MHC-I silencing, PD-L1 stabilization, and ferroptosis resistance; and in SCLC, USP1 mediates NK-cell evasion and MAST1-dependent cisplatin resistance, whereas USP13 sustains FASN-dependent cancer stem cell states. Therapeutic strategies are evolving from small-molecule inhibitors (GNE-6776, AZ1, and SJB2-043) to OTUB1-recruiting deubiquitinase-targeting chimeras (DUBTACs), DCAF-based PROTACs, and repurposed agents (rolapitant, ixazomib, and chidamide). Most evidence remains preclinical; substrate redundancy, validated biomarkers, and selectivity challenges must be addressed before DUB-directed strategies can be translated into biomarker-stratified combination therapies.